You're asking about **(3-hydroxyphenyl)-[4-(phenylmethyl)-1-piperazinyl]methanethione**, a chemical compound with a rather complex name. Here's what we can understand about it:
**Understanding the Structure and Chemical Properties:**
* **(3-hydroxyphenyl)-:** This indicates a phenyl ring (a six-membered carbon ring with alternating double bonds) with a hydroxyl group (-OH) attached to the third carbon atom.
* **[4-(phenylmethyl)-1-piperazinyl]:** This refers to a piperazine ring (a six-membered ring containing two nitrogen atoms) with a phenylmethyl group (a benzyl group, -CH2-C6H5) attached at the fourth carbon atom.
* **methanethione:** This indicates a thiocarbonyl group (-C=S) connected to a methyl group (-CH3).
**Putting it Together:**
The entire molecule is likely a complex organic compound with a combination of aromatic (phenyl) and heterocyclic (piperazine) rings, a hydroxyl group, and a thiocarbonyl group. The exact chemical structure is needed to fully understand its properties.
**Why it might be important for research:**
Unfortunately, without further context, it's difficult to say precisely why this specific compound is important for research. However, based on its structure, it could be relevant in:
* **Drug Discovery:** Compounds containing piperazine rings are often used as building blocks in pharmaceuticals, potentially acting as antihistamines, antipsychotics, or other therapeutic agents. The presence of a thiocarbonyl group and a hydroxyl group could add to its pharmacological activity.
* **Materials Science:** The combination of aromatic and heterocyclic rings, along with functional groups, might give this molecule interesting properties for use in polymers, coatings, or other materials.
* **Organic Chemistry Studies:** It could be a subject of study in organic chemistry research, exploring its reactivity, synthesis, or potential for use in novel synthetic pathways.
**To get a better understanding:**
* **More information is needed:** To determine the compound's specific importance, you'd need more information about its purpose in the research context.
* **Search for specific research:** You can try searching for the compound's name or a similar structure within scientific databases like PubChem or SciFinder to see if any relevant research has been conducted on it.
If you can provide more context (such as the research field, the study's goal, or the chemical source), it would be easier to understand why this specific compound is significant.
ID Source | ID |
---|---|
PubMed CID | 2204910 |
CHEMBL ID | 1326646 |
CHEBI ID | 123347 |
SCHEMBL ID | 17131913 |
Synonym |
---|
MLS000050509 , |
3-[(4-benzyl-1-piperazinyl)carbonothioyl]phenol |
smr000076439 |
CHEBI:123347 |
AKOS000351779 |
(4-benzylpiperazin-1-yl)-(3-hydroxyphenyl)methanethione |
HMS2367E14 |
CHEMBL1326646 |
bdbm34428 |
cid_2204910 |
(4-benzylpiperazino)-(3-hydroxyphenyl)methanethione |
(3-hydroxyphenyl)-[4-(phenylmethyl)piperazin-1-yl]methanethione |
(3-hydroxyphenyl)-[4-(phenylmethyl)-1-piperazinyl]methanethione |
Q27213056 |
SCHEMBL17131913 |
SR-01000275228-1 |
sr-01000275228 |
Class | Description |
---|---|
aromatic amine | An amino compound in which the amino group is linked directly to an aromatic system. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, HADH2 protein | Homo sapiens (human) | Potency | 3.1623 | 0.0251 | 20.2376 | 39.8107 | AID886 |
Chain B, HADH2 protein | Homo sapiens (human) | Potency | 3.1623 | 0.0251 | 20.2376 | 39.8107 | AID886 |
Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 79.4328 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
15-lipoxygenase, partial | Homo sapiens (human) | Potency | 12.5893 | 0.0126 | 10.6917 | 88.5700 | AID887 |
phosphopantetheinyl transferase | Bacillus subtilis | Potency | 12.5893 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 11.2202 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 19.9526 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
hemoglobin subunit beta | Homo sapiens (human) | Potency | 3.9811 | 0.3162 | 9.0861 | 31.6228 | AID925 |
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 14.1254 | 0.0018 | 15.6638 | 39.8107 | AID894 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 44.6684 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 15.0030 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Sphingosine 1-phosphate receptor 2 | Homo sapiens (human) | EC50 (µMol) | 50.0000 | 0.0007 | 0.3651 | 2.8530 | AID854 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
G protein-coupled receptor binding | Sphingosine 1-phosphate receptor 2 | Homo sapiens (human) |
G protein-coupled receptor activity | Sphingosine 1-phosphate receptor 2 | Homo sapiens (human) |
integrin binding | Sphingosine 1-phosphate receptor 2 | Homo sapiens (human) |
protein binding | Sphingosine 1-phosphate receptor 2 | Homo sapiens (human) |
lipid binding | Sphingosine 1-phosphate receptor 2 | Homo sapiens (human) |
G protein-coupled peptide receptor activity | Sphingosine 1-phosphate receptor 2 | Homo sapiens (human) |
sphingosine-1-phosphate receptor activity | Sphingosine 1-phosphate receptor 2 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
plasma membrane | Sphingosine 1-phosphate receptor 2 | Homo sapiens (human) |
postsynapse | Sphingosine 1-phosphate receptor 2 | Homo sapiens (human) |
plasma membrane | Sphingosine 1-phosphate receptor 2 | Homo sapiens (human) |
cytoplasm | Sphingosine 1-phosphate receptor 2 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |